Push launch written content from World Newswire. The AP information team was not involved in its development.
Click to duplicate
Push launch content from World Newswire. The AP information employees was not concerned in company monitoring software its development.
CAMBRIDGE, Mass., Oct. 01, 2020 (Globe NEWSWIRE) — Editas Drugs, Inc. (Nasdaq: EDIT), a primary genome editing business, nowadays announced that management will participate in the following forthcoming trader meeting:
Chardan Virtual 4th Once-a-year Genetic Medicines Convention
Date: Monday, October 5, 2020
Time: 10:30 a.m. ET
The celebration will be webcast reside and may perhaps be accessed on the Editas Medication web site in the Buyers and Media segment. Archived recordings will be offered for about 30 times subsequent the celebration.
About Editas Medication
As a major genome editing corporation, Editas Drugs is targeted on translating the electricity and possible of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome modifying devices into a strong pipeline of therapies for folks dwelling with severe health conditions around the world. Editas Medication aims to find, create, manufacture, and commercialize transformative, resilient, precision genomic medications for a wide course of illnesses. For the most up-to-date information and facts and scientific presentations, remember to stop by www.editasmedicine.com.